Last reviewed · How we verify

Roctavian — Competitive Intelligence Brief

Roctavian (VALOCTOCOGENE ROXAPARVOVEC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Rare Disease.

marketed Rare Disease Gene therapy Live · refreshed every 30 min

Target snapshot

Roctavian (VALOCTOCOGENE ROXAPARVOVEC) — BioMarin International Limited. Roctavian introduces a functional copy of the F8 gene into cells to produce factor VIII protein.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Roctavian TARGET VALOCTOCOGENE ROXAPARVOVEC BioMarin International Limited marketed 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Roctavian — Competitive Intelligence Brief. https://druglandscape.com/ci/valoctocogene-roxaparvovec. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing